# Safety of Cannabidiol in Healthy Adults: A Meta-Analysis Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-safety-healthy-adults-systematic-review/ > **Published:** 2026-03-20T17:43:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T15:54:42-04:00 > **Clinical Summary:** Explore CBD safety in healthy adults with this systematic review and meta-analysis comparing cannabidiol versus placebo effects. --- CED Clinical Relevance  #100High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic CbdSafetyRct[Adverse Events](https://cedclinic.com/cbd-endocrine-effects-gynecomastia-risk-safety/)Healthy Population Journal Annals of medicine and surgery (2012) Study Type [Randomized Trial](https://cedclinic.com/cannabis-cannabinoids-therapeutic-applications-review/) Population Human participants Why This Matters This is the first [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) specifically examining CBD safety in healthy populations, filling a critical evidence gap. Most safety data comes from patient populations where underlying conditions may confound adverse event profiles. Clinical Summary This meta-analysis of four RCTs involving 269 healthy adults found CBD significantly increased diarrhea risk compared to placebo (RR = 5.85). The study focused on common [adverse events](https://cedclinic.com/cbd-endocrine-effects-gynecomastia-risk-safety/) including headache, fatigue, abdominal pain, and respiratory symptoms. While the sample size was modest and limited to healthy volunteers, this represents the most rigorous safety assessment of CBD in non-patient populations to date. Dr. Caplan’s Take “This confirms what I observe clinically—diarrhea is CBD’s most predictable dose-limiting side effect, even in healthy individuals. The magnitude of risk increase aligns with my clinical experience across diverse patient populations.” Clinical Perspective 🧠 Clinicians should counsel patients that diarrhea remains the primary safety concern with CBD, regardless of health status. This data supports starting with lower doses and gradual titration, particularly in patients without prior CBD experience. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Safety%20of%20cannabidiol%20versus%20placebo%20in%20healthy%20population%3A%20a%20systematic%20review%20...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41789242/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41789242/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Safety%20of%20cannabidiol%20versus%20placebo%20in%20healthy%20population%3A%20a%20systematic%20review%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41789242/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41789242/](https://pubmed.ncbi.nlm.nih.gov/41789242/) Table of Contents - [FAQ](#FAQ)[What studies and side effects did this CBD safety meta-analysis examine?](#What_studies_and_side_effects_did_this_CBD_safety_meta-analysis_examine) - [Which side effect was most clearly linked to CBD in healthy adults?](#Which_side_effect_was_most_clearly_linked_to_CBD_in_healthy_adults) - [Why study CBD safety in healthy people rather than patients?](#Why_study_CBD_safety_in_healthy_people_rather_than_patients) - [What are the main limitations of this CBD safety review?](#What_are_the_main_limitations_of_this_CBD_safety_review) - [Related](#Related) ## FAQ ### What studies and side effects did this CBD safety meta-analysis examine? The meta-analysis combined four randomized controlled trials involving 269 healthy adults and compared CBD with placebo. It focused on common adverse events, including headache, fatigue, abdominal pain, and respiratory symptoms, as well as diarrhea. ### Which side effect was most clearly linked to CBD in healthy adults? Diarrhea was the clearest finding. Compared with placebo, CBD significantly increased the risk of diarrhea in healthy adults, with a relative risk (RR) of 5.85 across the four randomized trials included in the analysis. ### Why study CBD safety in healthy people rather than patients? Most CBD safety data come from patient populations, where underlying medical conditions may confound the pattern of adverse events. Studying healthy volunteers avoids that problem. The article describes this as the first [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) specifically examining CBD safety in healthy populations, filling a critical evidence gap. ### What are the main limitations of this CBD safety review? The sample size was modest and the trials were limited to healthy volunteers, so the results may not describe how CBD affects people with medical conditions. Even with these limits, the article describes the analysis as the most rigorous safety assessment of CBD in non-patient populations to date. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Safety of cannabidiol versus placebo in healthy population: a systematic review and meta-analysis.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41789242/”, “about”: “annals medicine surgery 2012 randomized trial”, “isPartOf”: “Annals of medicine and surgery (2012)”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Study: Low-Dose CBD Found Safe for People With HIV on Long-Term Antiretroviral Therapy …](https://cedclinic.com/cbd-safety-hiv-patients-low-dose-study/) Explore research on the safety of low-dose CBD in people with HIV undergoing long-term antiretroviral therapy, highlighting clinical implications. [Read Study](https://cedclinic.com/cbd-safety-hiv-patients-low-dose-study/) [Should cannabis be used for mental illnesses? – indica News](https://cedclinic.com/cannabinoid-efficacy-for-mental-health/) An insightful discussion on the potential role and safety considerations of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in mental illness treatment. [Learn More](https://cedclinic.com/cannabinoid-efficacy-for-mental-health/) [Potency-related effects of smoked cannabis on simulated driving performance: a randomized, controlled crossover trial.](https://cedclinic.com/cannabis-driving-impairment-effects-potency-safety/) Review findings on how cannabis potency affects driving performance, emphasizing safety and [risk assessment](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/). [Explore Findings](https://cedclinic.com/cannabis-driving-impairment-effects-potency-safety/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).